ATE486286T1 - Prognoseverfahren für kongestives herzversagen - Google Patents

Prognoseverfahren für kongestives herzversagen

Info

Publication number
ATE486286T1
ATE486286T1 AT05757019T AT05757019T ATE486286T1 AT E486286 T1 ATE486286 T1 AT E486286T1 AT 05757019 T AT05757019 T AT 05757019T AT 05757019 T AT05757019 T AT 05757019T AT E486286 T1 ATE486286 T1 AT E486286T1
Authority
AT
Austria
Prior art keywords
heart failure
congestive heart
methods
natriurctic
combination
Prior art date
Application number
AT05757019T
Other languages
English (en)
Inventor
Jean-Marie Ketelslegers
Michel Rousseau
Original Assignee
Biomedica Medizinprodukte Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedica Medizinprodukte Gmbh filed Critical Biomedica Medizinprodukte Gmbh
Application granted granted Critical
Publication of ATE486286T1 publication Critical patent/ATE486286T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5754—Endothelin, vasoactive intestinal contractor [VIC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT05757019T 2004-03-19 2005-03-18 Prognoseverfahren für kongestives herzversagen ATE486286T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55485904P 2004-03-19 2004-03-19
PCT/IB2005/002063 WO2005089045A2 (en) 2004-03-19 2005-03-18 Prognostic methods for congestive heart failure

Publications (1)

Publication Number Publication Date
ATE486286T1 true ATE486286T1 (de) 2010-11-15

Family

ID=34994109

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05757019T ATE486286T1 (de) 2004-03-19 2005-03-18 Prognoseverfahren für kongestives herzversagen

Country Status (7)

Country Link
US (1) US20070212729A1 (de)
EP (4) EP2267455A3 (de)
AT (1) ATE486286T1 (de)
DE (1) DE602005024389D1 (de)
DK (1) DK1756583T3 (de)
ES (1) ES2352845T3 (de)
WO (1) WO2005089045A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3086149A1 (en) 2006-04-04 2007-10-11 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
AU2010259022B2 (en) 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
JP7270912B2 (ja) * 2017-05-22 2023-05-11 東ソー株式会社 アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3516655B2 (ja) * 1997-09-11 2004-04-05 塩野義製薬株式会社 Ｂｎｐの免疫測定法
AUPQ048799A0 (en) * 1999-05-20 1999-06-10 Monash University Diagnosis of cardiovascular disease
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof

Also Published As

Publication number Publication date
EP2267455A3 (de) 2012-01-04
EP1756583B1 (de) 2010-10-27
WO2005089045A2 (en) 2005-09-29
WO2005089045A3 (en) 2006-07-20
EP2267456A2 (de) 2010-12-29
DE602005024389D1 (de) 2010-12-09
EP2267456A3 (de) 2011-08-17
EP2267455A2 (de) 2010-12-29
ES2352845T3 (es) 2011-02-23
EP2264463A2 (de) 2010-12-22
EP2264463A3 (de) 2011-08-10
DK1756583T3 (da) 2011-02-14
EP1756583A2 (de) 2007-02-28
US20070212729A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
DK3059322T3 (da) Genekspressionsmarkører for brystcancerprognose
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2010056351A3 (en) Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia
MX2007006529A (es) Seleccionar pacientes para terapia con un inhibidor her.
HK1063423A1 (en) Methods to diagnose treat and prevent bone loss
MX2009000385A (es) Acil-anilidas sustituidas y metodos de uso de las mismas.
GEP20166454B (en) Sclerostin binding agents
EP1810026A4 (de) B7-h1 und verfahren zur diagnose, prognose und behandlung von krebs
WO2004022580A3 (en) Bh3 peptides and method of use thereof
WO2004071572A3 (en) Gene expression markers for response to egfr inhibitor drugs
MX2009001962A (es) Acilanilidas substituidas y metodos de uso de las mismas.
CR10022A (es) Agentes que se enlazan con un objetivo en el tejido pulmonar para el tratamiento de enfermedades respiratorias
WO2005020784A3 (en) Surrogate cell gene expression signatures for evaluating the physical state of a subject
TW200636076A (en) Method for measuring resistance or sensitivity to docetaxel
RS20050132A (en) Use of cgrp antagonist compounds for treatment of psoriasis
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
WO2010054288A3 (en) Diagnosis and treatment of autoimmune diseases by targeting autoimmune-related b cells ("abcs")
ATE486286T1 (de) Prognoseverfahren für kongestives herzversagen
WO2005065365A3 (en) Systems and methods for aesthetic improvement
BRPI0502615A (pt) método para recomendar um programa de tratamento/prevenção da acne
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
NO20070780L (no) Celloverflateprotein.
BRPI0512709A (pt) métodos para prognóstico da resposta terapêutica a agentes atuando no receptor do hormÈnio do crescimento
ATE521893T1 (de) P66-shc als prädiktiver marker bei der krebsbehandlung
WO2005068663A3 (en) Methods of using peroxisome proliferator-activated receptor alpha target genes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1756583

Country of ref document: EP